Soluble Flt-1 gene therapy for peritoneal metastases using HVJ-cationic liposomes

Gene Therapy

Volumn 7, Issue 12, 2000, Pages 1027-1033

  Mori, A ^a   Arii, S ^a   Furutani, M ^a   Mizumoto, M ^a   Uchida, S ^a   Furuyama, H ^a   Kondo, Y ^a   Gorrin Rivas, M J ^a   Furumoto, K ^a   Kaneda, Y ^b   Imamura, M ^a  

^a KYOTO UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Gene therapy; HVJ liposome; Peritoneal metastasis; Soluble Flt 1

Indexed keywords

CATION; COMPLEMENTARY DNA; LIPOSOME; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; ENCAPSULATION; FIBROSARCOMA; GENE THERAPY; GENE TRANSFER; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MICROVASCULATURE; MOUSE; NONHUMAN; PARAINFLUENZA VIRUS 1; PERITONEUM METASTASIS; PRIORITY JOURNAL; RECEPTOR GENE; STOMACH CANCER; SURVIVAL TIME;

ANIMALIA; HUMAN PARAINFLUENZA VIRUS 1;

EID: 0343091294     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301202     Document Type: Article

References (43)

1. Folkman J. Tumor angiogenesis. Adv Cancer Res 1985; 43: 175-203.
2. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for endothelial cells. Biochem Biophys Res Commun 1989; 161: 851-858.
3. Brown LF et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its adenocarcinomas of the gastrointestinal tract. Cancer Res 1993; 53: 4727-4735.
4. Plate KH et al. Upregulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 1993; 53: 5822-5827.
5. Suzuki K et al. Expression of vascular permeability factor/ vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res 1996; 56: 3004-3009.
6. Kim KJ et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841-844.
7. Millauer B et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994; 367: 576-579.
8. Takahashi Y et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55: 3694-3968.
9. Warren RS et al. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995; 95: 1789-1797.
10. 121. Cancer Res 1995; 55: 5296-5301.
11. Mise M et al. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver. Hepatology 1996; 23: 455-464.
12. Cheng SY et al. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci USA 1996; 93: 8502-8507.
13. Saleh M, Stacker SA, Wilks AF. Inhibition of growth of C6 glioma cells in vivo by antisense vascular endothelial growth factor sequence. Cancer Res 1996; 56: 393-401.
14. Mori A et al. VEGF-induced tumor angiogenesis and tumorigenicity in relation to metastasis in a HT1080 fibrosarcoma cell line. Int J Cancer 1999; 80: 738-743.
15. Shibuya M et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to fms family. Oncogene 1990; 5: 519-524.
16. Terman BI et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor. Biochem Biophys Res Commun 1992; 187: 1579-1586.
17. de Vries C et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992; 255: 989-991.
18. Millauer B et al. A high affinity VEGF binding and development expression suggest FLK-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993; 72: 835-846.
19. Finnerty H et al. Molecular cloning of murine FLT and FLT4. Oncogene 1993; 8: 2293-2298.
20. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993; 90: 10705-10709.
21. Roeckl W et al. Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2. Exp Cell Res 1998; 241: 161-170.
22. Hiratsuka S et al. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 1998; 95: 9349-9354.
23. Lin P et al. Inhibition of tumor growth by targeting endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ 1998; 9: 49-58.
24. Goldman CK et al. Paracrine expression of native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis and mortality rate. Proc Natl Acad Sci USA 1998; 95: 8795-8800.
25. Kong HL et al. Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of flt-1 vascular endothelial growth factor receptor. Hum Gene Ther 1998; 9: 823-833.
26. Aoki K et al. Gene therapy for peritoneal dissemination of pancreatic cancer by liposome-mediated transfer of herpes simplex virus thymidine kinase gene. Hum Gene Ther 1997; 8: 1105-1113.
27. Nakanishi M et al. Efficient introduction of contents of liposomes into cells using HVJ (Sendai virus). Exp Cell Res 1985; 159: 399-409.
28. Kaneda Y et al. The improved efficient method for introducing macromolecules into cells using HVJ (Sendai virus) liposomes with gangliosides. Exp Cell Res 1987; 173: 56-69.
29. Saeki Y et al. Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus): reciprocal effect of cationic lipid for in vitro and in vivo gene transfer. Hum Gene Ther 1997; 8: 2133-2141.
30. Senger DR et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-985.
31. Morishita R et al. Single intraluminal delivery of antisense cdc2 kinase and proliferating-nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA 1993; 90: 8474-8478.
32. Sawa Y et al. Efficiency of in vivo gene transfection into transplanted rat heart by coronary infusion of HVJ liposome. Circulation 1995; 92: 479-482.
33. Hirano T et al. Persistent gene expression in rat liver in vivo by repetitive transfections using HVJ-liposome. Gene Therapy 1998; 5: 459-464.
34. Ueki T et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rat. Nature Med 1999; 5: 226-230.
35. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404-407.
36. Folkman J. Antiangiogenic gene therapy. Proc Natl Acad Sci USA 1998; 95: 9064-9066.
37. Kaneda Y, Iwai K, Uchida T. Increased expression of DNA cointroduced with nuclear protein in adult rat liver. Science 1989; 243: 375-378.
38. Wilke M et al. Efficacy of a peptide-based gene delivery system depends on mitotic activity. Gene Therapy 1996; 3: 1133-1142.
39. Mabuchi E et al. Gene delivery by HVJ-liposome in the experimental gene therapy of murine glioma. Gene Therapy 1997; 4: 768-772.
40. Kikuchi A et al. Development of novel cationic liposomes for efficient gene transfer into peritoneal disseminated tumor. Hum Gene Ther 1999; 10: 947-955.
41. Hirashima M et al. Maturation of embryonic stem cells into endothelial cells in an in vitro model of vasculogenesis. Blood 1999; 93: 1253-1263.
42. Maddon PJ et al. The isolation and nucleotide sequence of a cDNA encoding the T cell surface protein T4: a new member of the immunoglobulin gene family. Cell 1985; 42: 93-104.
43. Gao X, Huang L. A novel cationic liposomes reagent for efficient transfection of mammalian cells. Biochem Biophys Res Commun 1991; 179: 280-285.